Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1002/pmrj.12060 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
In the field of image processing, optical neural networks offer advantages such as high speed, high throughput, and low energy consumption. However, most existing coherent optical neural networks (CONN) rely on coherent light sources to establish transmission models. The use of laser inputs and electro-optic modulation devices at the front end of these neural networks diminishes their computational capability and energy efficiency, thereby limiting their practical applications in object detection tasks.
View Article and Find Full Text PDFIn space-based gravitational wave detection, establishing ultra-long-distance and ultra-high-precision laser links between satellites is achieved through the laser acquisition and tracking system. The laser spot centroid positioning method, which offers low computational complexity and strong adaptability to beam shape, is currently the core measurement method during the laser acquisition phase. However, due to various interference factors encountered in practical tests, this algorithm often falls short of meeting the extremely high requirements.
View Article and Find Full Text PDFLipid-Lowering Efficiency and Safety of Alirocumab 300 mg Using a 2-mL Autoinjector Device in Real-World Practice: The MARS Study.
Drugs Real World Outcomes
January 2025
Department of Cardiology, Angiology and Intensive Care Medicine, German Heart Center of the Charité, Berlin, Germany.
Background: Alirocumab is a fully human monoclonal antibody to proprotein convertase subtilisin kexin type 9 used for the reduction of low-density lipoprotein cholesterol (LDL-C) in high-risk patients not reaching their LDL-C target. Recently, a 2-mL prefilled autoinjector has been developed to support the monthly 300-mg dosing regimen with a single-injection administration.
Methods And Objectives: Monthly application of 300 mg AlirRocumab (Praluent) using the 2-mL SYDNEY Device (MARS) is a non-interventional, open, prospective, multi-center cohort study conducted in Germany between 2021 and 2023 with an observational period of 12 weeks.
Interleukin-23 versus Interleukin-17 Inhibitors in Preventing Incidental Psoriatic Arthritis in Patients with Psoriasis: A Real-World Comparison From the TriNetX US Collaborative Network.
BioDrugs
January 2025
Institute of Medicine, Chung Shan Medical University, Taichung, Taiwan.
Background: Psoriatic arthritis (PsA) is a common comorbidity in patients with psoriasis (PsO) that leads to significant disease burden. Biologic therapies targeting the interleukin (IL)-23/IL-17 axis have been widely used for PsO, but their comparative effectiveness in preventing PsA remains unclear.
Objective: The study objective was to compare the occurrence of developing incidental PsA among PsO patients treated with interleukin-23 inhibitors (IL23is) or interleukin-17 inhibitors (IL17is).
Enhancing spectral imaging with multi-condition image fusion.
Sci Rep
January 2025
Centre for Applied Photonics, INESC TEC, Rua do Campo Alegre 687, 4169-007, Porto, Portugal.
Spectral Imaging techniques such as Laser-induced Breakdown Spectroscopy (LIBS) and Raman Spectroscopy (RS) enable the localized acquisition of spectral data, providing insights into the presence, quantity, and spatial distribution of chemical elements or molecules within a sample. This significantly expands the accessible information compared to conventional imaging approaches such as machine vision. However, despite its potential, spectral imaging also faces specific challenges depending on the limitations of the spectroscopy technique used, such as signal saturation, matrix interferences, fluorescence, or background emission.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!